We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CombiMatrix, Universal Diagnostic Laboratories Announce Agreement
News

CombiMatrix, Universal Diagnostic Laboratories Announce Agreement

CombiMatrix, Universal Diagnostic Laboratories Announce Agreement
News

CombiMatrix, Universal Diagnostic Laboratories Announce Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CombiMatrix, Universal Diagnostic Laboratories Announce Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CombiMatrix Corporation has announced that Universal Diagnostic Laboratories will market and distribute CombiMatrix's chromosomal microarray miscarriage analysis test for the evaluation of multiple pregnancy loss in both Northern and Southern California. Terms of the agreement were not disclosed.

“This is another example of leveraging channel partners to augment our direct sales team's efforts in expanding the distribution of our tests,” said Mark McDonough, President and Chief Executive Officer of CombiMatrix. “Our miscarriage analysis test is now more accessible to women in our home state of California. We are pleased to partner with Universal Diagnostics Laboratories, which shares our commitment to high-touch, personalized service and excellent turnaround times.”

“This agreement demonstrates execution on a key aspect of our business strategy by expanding our portfolio of molecular diagnostics focused on women's health,” said Michael Mosunic, President and Chief Operating Officer of Universal Diagnostic Laboratories.

“Importantly, this test provides valuable information to women and their families about the reasons behind multiple miscarriages. We are particularly excited about the CombiMatrix test as chromosomal microarray analysis has shown to have superior diagnostic attributes over karyotyping for recurrent pregnancy loss.”

Advertisement